Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 3Lymphoid 1

Conditions

Lymphoma, Follicular 1Astrocytoma 1

Interventions

Cyclophosphamide 32Rituximab 24zanubrutinib 19Vincristine 16fludarabine 14Prednisone 14Magnetic Resonance Spectroscopy 14venetoclax 13blinatumomab 13Specimen Handling 13Doxorubicin 13Bendamustine Hydrochloride 11obinutuzumab 10Lenalidomide 9Dexamethasone 9polatuzumab vedotin 8Methotrexate 8Biopsy 8glofitamab 7Prednisolone 7Cytarabine 7Radiotherapy 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6pirtobrutinib 5pegaspargase 5Immunotherapy, Adoptive 5tislelizumab 4tafasitamab 4selinexor 4orelabrutinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × vorasidenib × Lymphoid × Clear all
NCT07215910 2025-10-14

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

Alliance for Clinical Trials in Oncology

Phase 3 Not yet recruiting
408 enrolled
CNSLymphoid

Astrocytoma, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡